The report from the American Diabetes Association and European Association for the Study of Diabetes offers guidance on diagnosis, management, and treatment, among other topics. Their recommendations are evidence-based where possible but represent the consensus opinion of the authors.
Results of a systematic review and meta-analysis were consistent across age groups, diabetes types, and regions of the world. The study authors suggested that earlier vaccination against herpes zoster in all patients with diabetes, regardless of age, be considered.
A retrospective study of veterans with diabetes found that those who started statin therapy were more likely to meet criteria for diabetes progression, such as initiation of insulin or an additional antihyperglycemic drug class, over time.
This month's quiz asks readers to evaluate a 52-year-old woman during a follow-up visit for hypertension management. She has a 10-year history of type 2 diabetes mellitus. Diabetic retinopathy was diagnosed one year ago.
Several new studies showed that among patients with type 1 diabetes, glycemic control improved and diabetic ketoacidosis decreased during COVID-19 lockdowns, while patients with type 2 diabetes showed the opposite trend during the pandemic.
The retrospective, nonrandomized comparison also found that risk for myocardial infarction or stroke differed by whether type 2 diabetes patients had cardiovascular disease at the time they started a sodium-glucose cotransporter-2 (SGLT-2) inhibitor or glucagon-like peptide-1 (GLP-1) receptor agonist.
In type 1 diabetes, real-time vs. intermittently scanned continuous glucose monitoring improved glycemic control
Clinicians can use the results of a recent European trial to reassure patients that good glycemic control can be achieved with either device, although real-time monitoring may be beneficial for those with more hypoglycemia issues, an ACP Journal Club commentary said.
A product complaint reported that the vial of glucagon in the kit was in liquid form instead of powder form. This could cause it to fail to treat severe hypoglycemia due to loss of potency, the FDA said.